Connect with us

Health

Oxford’s malaria vaccine shows significant 75% efficacy in early trial – BSA bureau

Being the first malaria vaccine candidate to meet WHO standards, the collaborative efforts of Novavax and Serum Institute of India (SII) aims to produce 200 million…

Published

on

Article feature image

Being the first malaria vaccine candidate to meet WHO standards, the collaborative efforts of Novavax and Serum Institute of India (SII) aims to produce 200 million doses annually upon further safety and efficacy results
A malaria vaccine created by scientists at the University of Oxford’s Jenner Institute has been found to be 77% effective in early-stage trials. It is the first malaria vaccine to meet the WHO’s target of 75%.
The Phase IIb trial of the vaccine candidate, R21, enrolled 450 children…

Click here to view the original article.

You might also like ...

Article feature image
Heart Disease Often Comes in Pairs – WebMD
Article feature image
Spinraza: SMA patients win fight over treatment loophole – BBC News
Article feature image
Americans missed almost 10 million cancer screenings during pandemic – Medical Xpress